Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06205927Phase 2Recruiting

Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer

Role: lead

NCT06186726Phase 2Recruiting

Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Role: lead

NCT06311955Phase 2Recruiting

Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Role: lead

NCT06311968Phase 2Recruiting

The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Role: lead

NCT06311981Phase 2Recruiting

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Role: lead

All 5 trials loaded